Teva Pharmaceutical Industries (TEVA) said Monday it plans to issue $2 billion equivalent of senior notes through its special purpose finance subsidiaries.
Teva Pharmaceutical Finance Netherlands II intends to offer euro-denominated notes, while Teva Pharmaceutical Finance Netherlands III and Teva Pharmaceutical Finance Netherlands IV aim to offer US dollar-denominated notes.
Separately, the company said it launched cash tender offers for up to $2 billion worth of certain series of notes. The offers are scheduled to expire at 5 pm ET June 17, unless extended or earlier terminated.
Teva said it expects to use the net proceeds from the planned notes issuance, along with cash on hand, to help fund the tender offers, among other things.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.